Bispecific Antibody Combinations Show High Response Rates in Aggressive Multiple Myeloma Studies

Recent clinical trials presented at the 2025 European Hematology Association Congress highlight promising advancements in multiple myeloma treatments. The MagnetisMM-6 trial demonstrated that the triplet combination of elranatamab, daratumumab, and lenalidomide achieved a nearly 100% overall response rate in transplant-ineligible newly diagnosed patients, with deepening responses expected over time. In aggressive extramedullary multiple myeloma, the phase 2 RedirecTT-1 study showed that the dual bispecific antibody combination of talquetamab and teclistamab achieved a 78.9% overall response rate, including durable responses in heavily pretreated patients, even those previously treated with BCMA CAR-T or bispecific antibodies. The TRIMM-3 trial revealed that combining talquetamab with the PD-1 inhibitor cetrelimab is safe and produces deep, durable responses with a median duration of response of 16.8 months in relapsed/refractory multiple myeloma patients. These findings underscore the potential of novel bispecific antibody combinations and immunotherapy partnerships to improve outcomes in both newly diagnosed and difficult-to-treat multiple myeloma populations. Experts emphasize that dual targeting strategies may overcome antigen escape mechanisms and offer new hope for patients with limited therapeutic options.